Search Results - "Militano, O"

Optimizing drug therapy in pediatric SCT: Focus on pharmacokinetics by McCune, J S, Jacobson, P, Wiseman, A, Militano, O

“…Given age-related differences in drug metabolism and indications for hematopoietic SCT (HSCT), personalized drug dosing of the conditioning regimen and…”
Get full text

Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma by Satwani, P, Jin, Z, Martin, P L, Bhatia, M, Garvin, J H, George, D, Chaudhury, S, Talano, J, Morris, E, Harrison, L, Sosna, J, Peterson, M, Militano, O, Foley, S, Kurtzberg, J, Cairo, M S

“…The outcome of children, adolescents and young adults (CAYA) with poor-risk recurrent/refractory lymphoma is dismal (⩽30%). To overcome this poor prognosis, we…”
Get full text

Safety of liposomal cytarabine CNS prophylaxis in children, adolescent and young adult hematopoietic stem cell transplant recipients with acute leukemia and non-Hodgkin lymphoma by Hochberg, J, Harrison, L, Morris, E, Militano, O, Brand, P, Fabricatore, S, Wolownik, K, Cairo, M S

Get full text

New frontiers in pediatric Allo-SCT by Talano, J M, Pulsipher, M A, Symons, H J, Militano, O, Shereck, E B, Giller, R H, Hancock, L, Morris, E, Cairo, M S

“…The inaugural meeting of ‘New Frontiers in Pediatric Allogeneic Stem Cell Transplantation’ organized by the Pediatric Blood and Transplant Consortium (PBMTC)…”
Get full text

Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases by BRADLEY, M. B, SATWANI, P, BAXTER-LOWE, L. A, SCHWARTZ, J, QUALTER, E, HAWKS, R, WOLOWNIK, K, FOLEY, S, MILITANO, O, LECLERE, J, CHEUNG, Y.-K, CAIRO, M. S, BALDINGER, L, MORRIS, E, VAN DE VEN, C, DEL TORO, G, GARVIN, J, GEORGE, D, BHATIA, M, ROMAN, E

“…There is a significant amount of morbidity and mortality following myeloablative umbilical cord blood transplantation (UCBT). Reduced intensity (RI)…”
Get full text

The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients by Le Gall, J B, Milone, M C, Waxman, I M, Shaw, L M, Harrison, L, Duffy, D, van de Ven, C, Militano, O, Geyer, M B, Morris, E, Bhatia, M, Satwani, P, George, D, Garvin, J H, Bradley, M B, Schwartz, J, Baxter-Lowe, L A, Cairo, M S

“…Intravenous BU divided four times daily (q6 h) has been shown to be safe and effective in pediatric allo-SCT recipients. Though less frequent dosing is…”
Get full text

Intravenous (IV) Busulfan (Bu) Administered Twice Daily During Conditioning Prior to Allogeneic Stem Cell Transplant (AlloSCT) in Pediatric Recipients Has Significantly Different Half-Life of Elimination and Clearance in Recipients >4 Years and Those ≤ 4 Years by LeGall, J.B, Milone, M, Waxman, I, Shaw, L, Harrison, L, Duffy, D, van de Ven, C, Militano, O, Geyer, M, Morris, E, Baxter Lowe, L, Cairo, M.S

Get full text

Iv Busulfan Administered Q12 Vs Q6 Hrs During Conditioning of Pediatric Allogeneic Stem Cell Transplant (AlloSCT) Recipients Has Comparable Pharmacokinetics and Significant Reduction in Nursing/Pharmacist Costs by LeGall, J, Milone, M.C, Waxman, I.M, Shaw, L.M, Harrison, L, Duffy, D, Militano, O, Bhatia, M, Satwani, P, George, D, Garvin, J.H, Bradley, M.B, van de Ven, C, Cairo, M.S

Get full text

Pharmacokinetics Of Mycophenolate Mofetil (MMF) In Combination With Tacrolimus In Pediatric Allogeneic Stem Cell Transplant (AlloSCT) Recipients ≤ 12 Years Of Age by Militano, O, Bhatia, M, Figurski, M, Shaw, L, Geyer, M.B, Jacobson, J.S, Morris, E, Satwani, P, George, D, Garvin, J.H, Cairo, M.S

Get full text

205: Low Molecular Weight Heparin (LMWH) Prophylaxis (PPX) in Pediatric Recipients following Pediatric Myeloablative Stem Cell Transplant (SCT) at High Risk for Sinusoidal Obstructive Syndrome (SOS): Is it Safe and Does it Make a Difference? by Rogoza, K, Bhatia, M, Baldinger, L, van de Ven, C, Militano, O, Qualter, E, Cairo, M.S

Get full text

Pharmacokinetics (PK) Of IV And Po Mycophenolate Mofetil (MMF) In Age Adjusted Pediatric And Adolescent Allogeneic Stem Cell Transplant (AlloSCT) Recipients: Significantly Higher CLss AND Vss IN PATIENTS <6 YEARS OF AGE by Militano, O, Bhatia, M, Jin, Z, Figurski, M, Shaw, L, Moore, V, Morris, E, Tallamy, B, van de Ven, C, Ayello, J, Baxter-Lowe, L.A, Satwani, P, George, D, Garvin, J.H, Cairo, M.S

Get full text

Twice-Daily Intravenous (IV) Busulfan (Bu) x 4 Days In Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) is Pharmacokinetically Similar to Q6 Hour Dosing in the Pediatric Population by Waxman, I, Milone, M.C, Bhatia, M, Shaw, L, Moore, V, Tallamy, B, Militano, O, Garvin, J.H, George, D, Bradley, M.B, Satwani, P, Schwartz, J, Wolownik, K, Foley, S, Hawks, R, Baxter-Lowe, L.A, van de Ven, C, Cairo, M.S

Get full text

229: Twice-Daily Intravenous (IV) Busulfan (Bu) x 4 Days in Children Undergoing a Reduced-Intensity Conditioning (RIC) Regimen with Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) is Safe and Well-Tolerated but Results in Significantly Increased Bu Clearance (CL) and Decreased Area Under the Curve (AUC) and Half-Life (t1/2 ) When Compared to IV Bu Twice-Daily Dosing Pharmacokinetics (PK) in Adults by Waxman, I, Bhatia, M, Milone, M, Shaw, L.M, Baldinger, L, Militano, O, Garvin, J, George, D, Bradley, M.B, Satwani, P, Schwartz, J, Wolownik, K, Foley, S, Hawks, R, Jin, Z.Z, Baxter-Lowe, L.A, van de Ven, C, Cairo, M.S

Get full text

202: Preliminary Results of a Phase I Study of Immuno-Chemotherapy (CTX) Conditioning with Gemtuzumab Ozogamicin (GO), Busulfan (Bu) and Cyclophosphamide (Cy) Followed by Allogeneic Stem Cell Transplantation (AlloSCT) in Pediatric Recipients with High Risk (HR) CD33+ Acute Myelogenous Leukemia (AML) by Waxman, I, Bhatia, M, Qualter, E, Jin, Z.Z, Kohl, V, Baldinger, L, Guerra, J, Garvin, J, George, D, Bradley, M.B, Satwani, P, Schwartz, J, Baxter-Lowe, L.A, Wolonik, K, Foley, S, Hawks, R, Militano, O, van de Ven, C, Mitchell, C.S

Get full text

185: Feasibility of autologous stem cell transplant followed by reduced intensity allogeneic stem cell transplantation for high risk neuroblastoma by Yamashiro, D.J, Lee, A, Bhatia, M, Glade-Bender, J, Qualter, E, Militano, O, Harrison, L.A, Davenport, V, Cheung, K, Bradley, M.B, Garvin, J.H, Del Toro, G, Cairo, M.S

Get full text

212: Adenovirus (ADV) infections following allogeneic stem cell transplant (alloSCT) in children and adolescent recepients by Oesterheld, J, George, D, Bradley, B, Del Toro, G, Garvin, J, Bhatia, M, Satwani, P, Roman, E, Cooney, E, Militano, O, Hawkes, R, Wowolnik, K, Foley, S, Schwartz, J, Cairo, M.S

Get full text

315: Pharmacokinetics (PK) of mycophenolate mofetil (MMF) in pediatric allogeneic stem cell transplant (AlloSCT) recipients by Militano, O, Hedgpeth, D, Shaw, L.M, Figurski, M, Satwani, P, Ayello, J, Roman, E, Bradley, B, George, D, Garvn, J, Bhatia, M, Wolownick, K, Foley, S, Hawkes, R, Cairo, M.S

Get full text

76: Reduced intenity allogeneic stem cell transplantion followed by targeted consolidation immunotherapy with gemtuzumab ozogamicin in children and adolescents with CD33+ acute myeloid leukemia by Roman, E, Cooney, E, Militano, O, Wolownik, K, Hawkes, R, Foley, S, Satwani, P, Guerra, J, Bhatia, M, Bradley, B, George, D, Garvin, J, Baxter-Lowe, L.A, Schwartz, J, Cheung, Y.-K, van de Ven, C, Cairo, M.S

Get full text

163: Systemic viral and fungal infections are not significantly decreased following reduced intensity allogeneic stem cell transplantation (RIAlloSCT) in children and adolescent recipients with malignant and nonmalignant diseases by Guerra, J, Satwani, P, Baldinger, L, van de Van, C, Roman, E, Garvin, J, Bradley, M.B, Bhatia, M, George, D, Schwartz, J, Hawkes, R, Wolownik, K, Foley, S, Morris, E, Militano, O, Cairo, M.S

Get full text

341: Reduced-intensity allogeneic umbilical cord blood transplantation (RI-UCBT) in pediatric recipients with malignant and non-malignant diseases by Satwani, P, Bradley, M.B, Baldinger, L, Morris, E, van de Ven, C, Garvin, J, George, D, Roman, E, Baxer-Lowe, L.A, Schwartz, J, Wolownik, K, Foley, S, Militano, O, Cheung, Y.-K, Cairo, M.S

Get full text